XTalks

FEBRUARY 5, 2024

Read on to learn more about the top 40 best-selling oncology drugs in 2023, based on 2022 sales data. Nevertheless, Opdivo continues to hold strong and Bristol Myers Squibb filed an application with the FDA in December for Opdivo in combination with cisplatin chemotherapy as a first-line treatment in advanced urothelial carcinoma.

FDA Approval 101

FDA Approval Drugs Sales Development 101

pharmaphorum

OCTOBER 12, 2021

The research by a team of National Institutes of Health (NIH) scientists found that people who took bumetanide, a generic drug usually used to treat heart failure and oedema, had a significantly lower prevalence of Alzheimer’s compared to those not taking the drug.

Gene Expression 111

Gene Expression Drugs FDA Approval Gene 111

XTalks

FEBRUARY 5, 2024

Read on to learn more about the top 40 best-selling oncology drugs in 2023, based on 2022 sales data. Nevertheless, Opdivo continues to hold strong and Bristol Myers Squibb filed an application with the FDA in December for Opdivo in combination with cisplatin chemotherapy as a first-line treatment in advanced urothelial carcinoma.

FDA Approval 52

FDA Approval Drugs Sales Development 52

pharmaphorum

DECEMBER 1, 2021

Sanofi said it would also apply its mRNA vaccine platform – acquired along with Translate Bio earlier this year – to find other acne vaccine candidates that could start clinical trials in 2023. Oral isotretinoin can also be effective but is associated with serious side effects so is generally a last-line option.

Vaccination 105

Vaccination Vaccine Development Hormones 105

Camargo

NOVEMBER 11, 2020

announced a collaboration to develop a companion diagnostic for Vitrakvi® (larotrectinib) NTRK (neurotrophic tropomyosin receptor kinase) inhibitor, approved in the U.S. In October, less than 18 months later, the FDA approved the companion test, which will allow physicians to better identify target eligible patients.

Development 242

Development Bioequivalency Generic Drugs Production 242

Pharmaceutical Technology

NOVEMBER 29, 2022

In 1970, the FDA approved ketamine as an anesthetic. In the Phase I/II study, the drug’s effect on pain intensity at 15 minutes after treatment did not meet the required efficacy threshold for the trial’s success, but some efficacy was observed after 30 minutes. Still, Funding is not the only issue.

Research 275

Research Trials Drugs Generic Drugs 275

XTalks

JUNE 8, 2022

Novartis’ biosimilars and generics drug division Sandoz has announced a new global campaign called ‘Act4Biosimilars’ to help raise awareness about biosimilars and increase their adoption by at least 30 percent in over 30 countries by the year 2030. Related: Cyltezo Becomes First FDA-Approved Interchangeable Humira Biosimilar.

Generic Pharmaceutical 69

Generic Pharmaceutical Branding Production Medicine 69